Aquestive Therapeutics Inc [AQST] Securities Class Action Lawsuit Update

• Case Name: Modica v. Aquestive Therapeutics, Inc., et al.
• Case No.: 3:26-cv-02317
• Jurisdiction: U.S. District Court, District of New Jersey
• Filed on: March 5, 2026
• Class Period: June 16, 2025 – January 8, 2026

Introduction

Aquestive Therapeutics said Anaphylm’s FDA review was on track. On January 9, 2026, the company disclosed that the FDA had identified deficiencies that could delay approval.

A securities class action has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its CEO Daniel Barber, alleging that investors were misled about the regulatory timeline for its lead product, Anaphylm. The lawsuit centers on claims that the company repeatedly assured the market that its New Drug Application (NDA) was on track for approval toward a January 31, 2026 FDA decision, while allegedly concealing material deficiencies that ultimately delayed approval.

When the truth surfaced on January 9, 2026, the market responded immediately. Shares fell more than 37% in a single trading session, erasing significant shareholder value.

“Most AQST shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Aquestive Therapeutics operates in the pharmaceutical sector, focusing on drug delivery technologies and treatments for central nervous system conditions and allergic reactions. One of the company’s key products during the period was Anaphylm, a sublingual film designed to treat severe allergic reactions, including anaphylaxis.

The company positioned Anaphylm as a disruptive alternative to traditional epinephrine delivery systems. Management emphasized its portability, ease of use, and potential to redefine emergency allergy treatment. The product’s near-term commercial prospects depended on FDA approval tied to the January 31, 2026 PDUFA date.

That timeline became the backbone of the company’s investor narrative.

Promises Made vs. Reality

Throughout the class period, Aquestive executives delivered a consistent message. Approval was on track. The process was described as routine. Nothing had been disclosed to suggest a material obstacle.

On August 12, 2025, CEO Daniel Barber told investors: “We are on track in our FDA review process… and our pre-commercial launch activities.” He reinforced that view by stating there was “nothing… beyond the standard 120-day safety update” in communications with the FDA.

By November, the tone remained unchanged. The company described its regulatory path as advancing and reaffirmed the January 31, 2026 action date. Investors were left with a clear impression. According to the complaint, defendants’ statements conveyed that Anaphylm remained on track for approval by the January 31, 2026 PDUFA date.

The complaint alleges that defendants concealed or minimized the significance of human factors issues tied to product use, including packaging, administration, and labeling. As alleged, these issues were significant and ultimately contributed to a delay in approval beyond the PDUFA date.

Timeline of Alleged Misconduct and Disclosures

The sequence unfolded with precision.

On June 16, 2025, Aquestive announced FDA acceptance of its NDA and highlighted the January 31, 2026 PDUFA date, framing it as a key milestone. Through August and November 2025, the company continued to affirm that its application was described as progressing in line with expectations, reinforcing investor expectations of timely approval.

Then came January 9, 2026. Aquestive disclosed that the FDA had identified deficiencies in its NDA that “preclude discussion of labeling and post-marketing commitments.” The disclosure indicated that approval would be delayed beyond the January 31, 2026 PDUFA date.

The market reacted instantly. Shares dropped from $6.21 to $3.91 in a single day.

Weeks later, on January 30, 2026, the FDA issued a Complete Response Letter confirming the concerns. The deficiencies involved human factors, including issues related to packaging, usability, and administration of the film.

Investor Harm and Market Reaction

The price collapse on January 9 followed the company’s disclosure of FDA-identified deficiencies. It was the market correcting a narrative that had been built over months.

Investors who purchased AQST shares during the class period allegedly did so under the belief that FDA approval was on track. That belief was reinforced by repeated executive statements and by the omission of material information bearing on the approval timeline.

When the FDA’s concerns became public, the inflation in the stock price, as alleged in the complaint, unwound quickly.

Analysts responded just as sharply. Cantor Fitzgerald cut its price target from $15 to $8, citing uncertainty and the increased risk of delay. Oppenheimer went further, warning that the deficiencies could lead to a Complete Response Letter and a delay of up to 12 to 15 months.

Loss causation, as alleged, is direct. The corrective disclosure revealed previously undisclosed regulatory risks. The stock price followed.

Litigation and Procedural Posture

The case, styled Modica v. Aquestive Therapeutics, Inc. et al., Case No. 3:26-cv-02317, is pending in the United States District Court for the District of New Jersey.

The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5.

Defendants include the company and CEO Daniel Barber. The allegations focus on materially false and misleading statements, omissions regarding FDA review risks, and scienter based on management’s alleged knowledge of NDA deficiencies.

The class period runs from June 16, 2025 through January 8, 2026.

Plaintiff alleges that the company’s statements artificially inflated the stock price and that investors suffered damages when the truth was revealed.

Shareholder Sentiment

Retail investor reaction appeared mixed following the January 9 disclosure. Some investors viewed the decline as a potential buying opportunity, while others expressed concern about the regulatory setback. Online discussion included debate over whether the identified ‘human factors’ issues represented a procedural delay or a more substantive hurdle. The disclosure also prompted increased scrutiny of prior management statements describing the FDA review as “on track.”

Analyst Commentary

Analysts who had previously modeled near-term approval were forced to reassess.

Cantor Fitzgerald cut its price target from $15 to $8, citing uncertainty and the increased risk of delay associated with the FDA’s feedback. The firm cited the history of Complete Response Letters following similar FDA communications, which increased the risk of delay for Anaphylm.

Oppenheimer’s analysis was more pointed. The firm warned that the late-stage nature of the FDA’s concerns increased the probability of a Complete Response Letter, which ultimately materialized.

The consensus view shifted from near-term commercialization to regulatory uncertainty. That shift was reflected in both price targets and risk assessments.

SEC Filings & Risk Factors

According to the complaint, defendants’ statements went beyond general optimism and created the impression that Anaphylm remained on track for approval by the January 31, 2026 PDUFA date. The complaint alleges that defendants failed to disclose or adequately convey information concerning issues that later delayed approval, including the significance of human factors considerations.

The alleged omission is central to the case. The FDA’s subsequent identification of deficiencies indicates that these issues were not merely hypothetical risks.

Conclusion: Implications for Investors

This case highlights the risks associated with regulatory timelines in the biotech sector.

Drug approval timelines are fragile. Small issues, particularly those tied to usability and safety, can delay or derail even well-advanced applications. When companies frame those timelines with certainty, the risk to investors increases.

For investors, the lesson is familiar but often ignored. Confidence from management is not the same as regulatory clearance.

And when the gap between the two widens, the market closes it quickly.

Now, investors are fighting back.

How to Join the Aquestive Therapeutics (AQST) Class Action

• Confirm you purchased AQST shares during the class period (June 16, 2025 to January 8, 2026)
• Review eligibility details based on your transaction history
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.